Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech
Executive Summary
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
You may also be interested in...
Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund
Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.
CSL Looks Beyond Organic Growth To External Innovation
CSL Ltd.'s sales grew 15% in its last fiscal year and are expected to grow about 8% in FY 2018, but the Australia-based company is looking beyond its plasma protein expertise to outside innovation to help boost future revenue.
Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab
Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.